Pharsight

Drugs that contain Mobocertinib Succinate

1. Exkivity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(11 years from now)

US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 15, 2026
Orphan Drug Exclusivity (ODE) Sep 15, 2028

NCE-1 date: 2025-09-15

Market Authorisation Date: 15 September, 2021

Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...

Dosage: CAPSULE;ORAL

More Information on Dosage

EXKIVITY family patents

Family Patents